Cantor Fitzgerald Decreases Earnings Estimates for Affimed

Affimed (NASDAQ:AFMD) – Equities research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for shares of Affimed in a research note issued on Tuesday, November 19th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earnings per share of ($4.06) for the year, down from their prior forecast of ($3.71). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%.

AFMD has been the subject of a number of other research reports. Stifel Nicolaus reduced their price target on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Affimed Price Performance

Shares of AFMD stock opened at $2.62 on Friday. Affimed has a 12-month low of $2.61 and a 12-month high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The business has a 50 day simple moving average of $3.38 and a 200 day simple moving average of $4.43.

Institutional Investors Weigh In On Affimed

Several hedge funds have recently modified their holdings of AFMD. Choreo LLC purchased a new position in Affimed in the 2nd quarter worth about $54,000. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Jane Street Group LLC purchased a new position in shares of Affimed in the third quarter worth approximately $44,000. FMR LLC lifted its position in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.